VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 201 filers reported holding VAXCYTE INC in Q3 2023. The put-call ratio across all filers is 0.83 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,423,311 | +12.5% | 27,919 | +10.2% | 0.03% | +21.4% |
| Q2 2023 | $1,265,679 | -17.0% | 25,344 | -37.7% | 0.03% | -9.7% |
| Q1 2023 | $1,524,574 | -30.8% | 40,677 | -11.4% | 0.03% | -39.2% |
| Q4 2022 | $2,202,583 | +345.0% | 45,935 | +102.1% | 0.05% | +292.3% |
| Q2 2022 | $495,000 | -32.5% | 22,733 | -25.1% | 0.01% | -23.5% |
| Q1 2022 | $733,000 | +3.8% | 30,369 | +2.3% | 0.02% | 0.0% |
| Q4 2021 | $706,000 | -6.2% | 29,680 | 0.0% | 0.02% | -19.0% |
| Q3 2021 | $753,000 | -31.9% | 29,680 | -39.6% | 0.02% | -41.7% |
| Q2 2021 | $1,106,000 | +1.9% | 49,121 | -10.6% | 0.04% | -12.2% |
| Q1 2021 | $1,085,000 | +39.8% | 54,931 | +88.0% | 0.04% | +41.4% |
| Q4 2020 | $776,000 | +39.1% | 29,212 | +65.6% | 0.03% | -23.7% |
| Q2 2020 | $558,000 | – | 17,637 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 1,049,893 | $53,523,545 | 17.09% |
| Pivotal bioVenture Partners Investment Advisor LLC | 793,036 | $40,429,128 | 16.12% |
| Kynam Capital Management, LP | 1,302,407 | $66,396,709 | 10.86% |
| RA Capital Management | 7,891,254 | $402,296,129 | 7.92% |
| COMMODORE CAPITAL LP | 1,100,000 | $56,078,000 | 6.56% |
| GREAT POINT PARTNERS LLC | 531,211 | $27,081,137 | 4.93% |
| ACUTA CAPITAL PARTNERS, LLC | 121,022 | $6,169,702 | 4.14% |
| Frazier Life Sciences Management, L.P. | 1,164,405 | $59,361,367 | 3.94% |
| Novo Holdings A/S | 845,000 | $43,078,100 | 3.18% |
| BRAIDWELL LP | 1,619,553 | $82,564,812 | 2.61% |